Overview

India is one of the fastest growing pharmaceutical markets in the world. Sale of branded products in India is integral to Lupin's business, and is a vital part of the Company's growth strategy. The Company's India formulations business contributed 27% to the company's revenues for FY 2012. The company's India formulations business has repeatedly outperformed the Indian Pharmaceutical Market (IPM) growing at a CAGR of around 20 % over the last 5 years. The India formulations business grew by 23% recording revenues of ` 19,374 million during FY 2012, as compared to ` 15,734 million in FY 2011

The measure of the quality of Lupin's sustained growth performance is not only in our growth numbers but also in our ability to continue to enter new segments and launching products that are first to market. The Company continues to improve its market share across all our therapy segments and has an overall market share of 2.82% of the IPM (ORG IMS MAT March 2012).

Sustained growth in revenues is an indicator of the quality of our sales force; the real strength behind our success in the Indian Pharmaceutical Market (IPM). During FY 2012, the Company augmented its field force to 4,800 personnel. Lupin today enjoys one of the highest productivity ratios per medical representative in the IPM.
 

CHRONIC THERAPY FOCUS
Lupin is focused on the lifestyle and chronic therapy segments with an eye on the leadership spot. Lupin's product and therapy segment mix for the IPM coupled with unrivaled marketing strategies has led to the Company emerging as amongst the fastest growing player in therapies like Cardiology, Central Nervous System (CNS), Diabetology, Anti-Asthma, Anti-Infective, Gastro Intestinal and Oncology.

Top Ten Lupin Brands (ORG IMS MAR 2013)

Lupin's growth in comparison with market (ORG IMS MAR 2013)

* Growth of Anti-diabetes portfolio is inclusive of Huminsulin